Lantheus Holdings Inc
$ 66.71
0.04%
26 Dec - close price
- Market Cap 4,535,890,000 USD
- Current Price $ 66.71
- High / Low $ 66.89 / 66.20
- Stock P/E 27.68
- Book Value 16.88
- EPS 2.41
- Next Earning Report 2026-02-19
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.10 %
- ROE 0.15 %
- 52 Week High 111.29
- 52 Week Low 47.25
About
Lantheus Holdings, Inc. is a prominent biotechnology company headquartered in North Billerica, Massachusetts, specializing in the development and commercialization of advanced diagnostic and therapeutic solutions, primarily targeting oncology and cardiology. Recognized for its innovative PET imaging agents, Lantheus is pivotal in enhancing the accuracy of cancer diagnosis and treatment management, thereby significantly improving patient outcomes. With a commitment to advancing healthcare through cutting-edge technology, Lantheus has solidified its position as a key player within the healthcare sector, driving innovation and improving patient care across its therapeutic focus areas.
Analyst Target Price
$82.43
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-06 | 2025-08-06 | 2025-04-30 | 2025-02-20 | 2024-11-06 | 2024-07-31 | 2024-05-02 | 2024-02-22 | 2023-11-02 | 2023-08-03 | 2023-05-04 | 2023-02-23 |
| Reported EPS | 1.27 | 1.12 | 1.53 | 1.59 | 1.7 | 1.8 | 1.69 | 1.75 | 1.47 | 1.54 | 1.47 | 1.37 |
| Estimated EPS | 1.28 | 1.67 | 1.6539 | 1.5431 | 1.56 | 1.83 | 1.54 | 1.45 | 1.32 | 1.31 | 1.26 | 0.96 |
| Surprise | -0.01 | -0.55 | -0.1239 | 0.0469 | 0.14 | -0.03 | 0.15 | 0.3 | 0.15 | 0.23 | 0.21 | 0.41 |
| Surprise Percentage | -0.7813% | -32.9341% | -7.4914% | 3.0393% | 8.9744% | -1.6393% | 9.7403% | 20.6897% | 11.3636% | 17.5573% | 16.6667% | 42.7083% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-19 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | 1.19 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: LNTH
2025-12-27 11:09:31
Harbor Capital Advisors Inc. significantly reduced its stake in Lantheus Holdings, Inc. ($LNTH) by 83.8% in the third quarter of 2025, selling 159,268 shares. Despite this, institutional ownership remains very high at 99.06%, with other major funds increasing or initiating new positions in the medical equipment provider. Wall Street analysts currently give Lantheus a "Moderate Buy" consensus rating with an average target price of $78.00.
2025-12-26 09:08:33
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Lantheus Holdings, Inc. (LNTH) regarding corporate wrongdoing. The firm encourages stockholders who purchased Lantheus securities before November 6, 2024, and still hold them, to inquire about the securities investigation. The firm operates on a contingency fee basis, aiming to recover investor capital and ensure corporate accountability.
2025-12-26 09:08:33
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into potential corporate wrongdoing by Lantheus Holdings, Inc. (NASDAQ:LNTH). The firm is encouraging stockholders who purchased Lantheus securities before November 6, 2024, and still hold them, to contact them to assist with the investigation. The investigation aims to recover investor capital and ensure corporate accountability.
2025-12-26 08:09:32
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lantheus Holdings, Inc. (NASDAQ:LNTH) who bought securities before November 6, 2024, and still hold them. The firm encourages stockholders to inquire about a securities investigation concerning potential corporate wrongdoing by Lantheus officers and/or directors. Investors can assist the investigation by visiting the firm's website or contacting their representatives.
2025-12-25 16:09:24
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Lantheus Holdings, Inc. (NASDAQ:LNTH) on behalf of investors who purchased securities prior to November 6, 2024, and continue to hold them. The investigation seeks to determine if Lantheus, its officers, and/or directors engaged in corporate wrongdoing. The law firm encourages affected stockholders to visit their website for more information and to assist in the investigation at no cost.
2025-12-24 09:09:51
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of investors who purchased Lantheus Holdings, Inc. (LNTH) securities prior to November 6, 2024, and continue to hold them. The investigation focuses on whether Lantheus and its officers engaged in corporate wrongdoing. The firm encourages affected investors to contact them for more information, emphasizing that there is no cost to investors as they work on a contingency fee basis.
